Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J, Gronwald J, Huzarski T, Aeilts A, Randall Armel S, Karlan B, Singer CF, Eisen A, Tung N, Olopade O, Bordeleau L, Eng C, Foulkes WD, Neuhausen SL, Cullinane CA, Pal T, Fruscio R, Lubinski J, Metcalfe K, Sun P, Narod SA; and the Hereditary Breast Cancer Clinical Study Group. Kotsopoulos J, et al. Among authors: neuhausen sl. Breast Cancer Res Treat. 2023 Sep;201(2):257-264. doi: 10.1007/s10549-023-06991-3. Epub 2023 Jul 11. Breast Cancer Res Treat. 2023. PMID: 37432545
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al. Tonin P, et al. Nat Med. 1996 Nov;2(11):1179-83. doi: 10.1038/nm1196-1179. Nat Med. 1996. PMID: 8898735 Review. No abstract available.
Cancer risks in BRCA2 mutation carriers.
Breast Cancer Linkage Consortium. Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6. doi: 10.1093/jnci/91.15.1310. J Natl Cancer Inst. 1999. PMID: 10433620
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Rebbeck TR, et al. Among authors: neuhausen sl. J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9. doi: 10.1093/jnci/91.17.1475. J Natl Cancer Inst. 1999. PMID: 10469748
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group. Narod SA, et al. Among authors: neuhausen sl. Lancet. 2000 Dec 2;356(9245):1876-81. doi: 10.1016/s0140-6736(00)03258-x. Lancet. 2000. PMID: 11130383
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Rebbeck TR, et al. Among authors: neuhausen sl. N Engl J Med. 2002 May 23;346(21):1616-22. doi: 10.1056/NEJMoa012158. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023993 Free article.
408 results